Yang Cheng, Chen Lei, Niu Qingsong, Ge Qintao, Zhang Jiong, Tao Junyue, Zhou Jun, Liang Chaozhao
Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Institute of Urology, Anhui Medical University, Hefei, China.
Cancer Cell Int. 2022 Dec 5;22(1):382. doi: 10.1186/s12935-022-02791-9.
It is well-established that biochemical recurrence is detrimental to prostate cancer (PCa). In the present study, we explored the mechanisms underlying PCa progression.
Five cohorts from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus databases were used to perform gene set variation analysis (GSVA) between nonrecurrent and recurrent PCa patients. We obtained the intersection of pathway enrichment results and extracted the corresponding gene list. LASSO Cox regression analysis was used to identify recurrence-free survival (RFS)-related significant genes and establish an RFS prediction gene signature and nomogram. MTT and colony formation assays were conducted to validate our findings.
The E2F signaling pathway was activated in recurrent PCa patients compared to nonrecurrent patients. We established an E2F-related gene signature for RFS prediction based on the four identified E2F-related genes (CDKN2C, CDKN3, RACGAP1, and RRM2) using LASSO Cox regression in the Memorial Sloan Kettering Cancer Center (MSKCC) cohort. The risk score of each patient in MSKCC was calculated based on the expression levels of CDKN2C, CDKN3, RACGAP1, and RRM2. PCa patients with low-risk scores exhibited higher RFS than those with high-risk scores. Receiver operating characteristic (ROC) curve analysis validated the good performance and prognostic accuracy of the E2F-related gene signature, which was validated in the TCGA-prostate adenocarcinoma (TCGA-PRAD) cohort. Compared to patients with low Gleason scores and early T stages, PCa patients with high Gleason scores and advanced T stages had high-risk scores. Moreover, the E2F-related gene signature-based nomogram yielded good performance in RFS prediction. Functional experiments further confirmed these results.
The E2F signaling pathway is associated with biochemical recurrence in PCa. Our established E2F-related gene signature and nomogram yielded good accuracy in predicting the biochemical recurrence in PCa.
生化复发对前列腺癌(PCa)有害,这一点已得到充分证实。在本研究中,我们探讨了PCa进展的潜在机制。
使用来自癌症基因组图谱(TCGA)和基因表达综合数据库的五个队列,对未复发和复发PCa患者进行基因集变异分析(GSVA)。我们获取了通路富集结果的交集并提取了相应的基因列表。采用LASSO Cox回归分析来识别无复发生存(RFS)相关的显著基因,并建立RFS预测基因特征和列线图。进行MTT和集落形成试验以验证我们的发现。
与未复发患者相比,复发PCa患者的E2F信号通路被激活。我们在纪念斯隆凯特琳癌症中心(MSKCC)队列中,基于使用LASSO Cox回归确定的四个E2F相关基因(CDKN2C、CDKN3、RACGAP1和RRM2),建立了用于RFS预测的E2F相关基因特征。根据CDKN2C、CDKN3、RACGAP1和RRM2的表达水平计算MSKCC中每位患者的风险评分。低风险评分的PCa患者比高风险评分的患者表现出更高的RFS。受试者操作特征(ROC)曲线分析验证了E2F相关基因特征的良好性能和预后准确性,该特征在TCGA-前列腺腺癌(TCGA-PRAD)队列中得到了验证。与低Gleason评分和早期T分期的患者相比,高Gleason评分和晚期T分期的PCa患者具有高风险评分。此外,基于E2F相关基因特征的列线图在RFS预测中表现良好。功能实验进一步证实了这些结果。
E2F信号通路与PCa的生化复发相关。我们建立的E2F相关基因特征和列线图在预测PCa的生化复发方面具有良好的准确性。